Literature DB >> 6198729

Immunologic therapies of kidney carcinoma.

C S McCune.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6198729

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  3 in total

Review 1.  Rationale for immunotherapy of renal cell carcinoma.

Authors:  R Heicappell; R Ackermann
Journal:  Urol Res       Date:  1990

2.  Gemcitabine: a phase II study in patients with advanced renal cancer.

Authors:  P H De Mulder; L Weissbach; G Jakse; R Osieka; J Blatter
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

3.  EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group.

Authors:  P H De Mulder; G Oosterhof; C Bouffioux; A T van Oosterom; K Vermeylen; R Sylvester
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.